Onyx Pharmaceuticals to acquire Proteolix

November 2009
PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p33
Market Research Report
The article reports on the signed definitive agreement to acquire biopharmaceutical company Proteolix Inc. by Onyx Pharmaceuticals Inc. It notes that Proteolix is set to be paid 276 million dollars upon finalization of the transaction in the fourth quarter of 2009. It mentions that Proteolix is a company specializing in discovering and developing novel therapies for hematological malignancies and solid tumors treatment. It details the terms of the transaction.


Related Articles

  • Onyx's Proteolix Grab: Pipeline Backfill - and Maybe MM Ticket. Osborne, Randy // BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p3 

    The article reports on the possible approval of carfilzomib, which is said to have driven the 851 million-dollar buyout of Proteolix Inc. by Onyx Pharmaceuticals Inc. It states that the proteasome inhibitor is similar to the Velcade drug. It notes that Onyx considers the deal with Proteolix as a...

  • For $339M Onyx Carves Out Carfilzomib Japanese Rights. Morrison, Trista // BioWorld Today;9/9/2010, Vol. 21 Issue 174, p1 

    The article focuses on the acquisition of Proteolix Inc. by Onyx Pharmaceuticals Inc. Under the deal, Onyx Pharmaceuticals Inc., which will market carfilzomib by itself in the U.S. and Europe, will take 59 million U.S. dollars up front, 280 million U.S. dollars in potential milestones and...

  • Proteolix's Proteasome Inhibitor Drives Onyx Deal.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p3 

    The article reports that Emeryville, California-based Onyx Pharmaceuticals Inc. has agreed to acquire Proteolix Inc. of South Francisco, California in a potential deal worth 851 million dollars. It notes that the acquisition of Proteolix Inc. aims to help Onyx expand its pipeline to bridge the...

  • Proteolix's Proteasome Inhibitor Drives Much-Awaited Onyx Deal. Boggs, Jennifer // BioWorld Today;10/13/2009, Vol. 20 Issue 197, p1 

    The article reports on the acquisition of Proteolix Inc. by Onyx Pharmaceuticals Inc. The acquisition was centered on carfilzomib, which is a proteasome inhibitor for multiple myeloma. Carfilzomib is aimed to bridge the gap between an approved cancer drug, Nexavar (sorafenib), and two...

  • Onyx Pharmaceuticals completes acquisition of Proteolix.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p26 

    The article reports on the acquisition of the biopharmaceutical company Proteolix Inc. by Onyx Pharmaceuticals Inc. for the development of medical therapies against hematological tumors. According to Onyx chief executive officer (CEO), Anthony Coles, the acquisition places the firm as a...

  • Proteolix Will Be Acquired by Onyx.  // Chain Drug Review;10/26/2009, Vol. 31 Issue 18, p74 

    The article reports on the plan of Onyx Pharmaceuticals Inc. to acquire Proteolix Inc. in the U.S. According to Onyx, it will purchase the cancer drug developer in a deal that could be worth as much as 851 million dollars. Onyx will pay 276 million dollars up front, 40 million dollars for...

  • WEEK IN REVIEW.  // BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p6 

    The article presents financings and deals of pharmaceutical companies. Adventrx Pharmaceuticals Inc. received a gross income of 11.3 million dollars from its registered direct offering of stock and warrants. Allos Therapeutics Inc. obtained on its disclosed public stock offering a net income of...

  • GSK Weighing Options for Montrose Pharma Plant.  // Chemical Market Reporter;6/2/2003, Vol. 263 Issue 22, p6 

    Reports that GlaxoSmithKline PLC (GSK) is still seeking a buyer for its pharmaceutical plant at Montrose, Scotland, following the withdrawal of Azko Nobel's Diosynth from negotiations to buy the unit in March 2003. Basis for Diosynth's decision not to buy the Montrose plant; Reason why GSK...

  • Deal watch: M&A activity in 2009. Walker, Josef // Nature Reviews Drug Discovery;Feb2010, Vol. 9 Issue 2, p95 

    The article offers information on the mergers and acquisitions (M&As) of the top 50 pharmaceuticals across the globe in 2009. It mentions that M&As were dominated by mega-mergers with three deals that surpass the 40 billion U.S. dollars mark. It is stated that the total value of the deals in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics